Iovance Biotherapeutics/$IOVA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Ticker

$IOVA
Sector
Primary listing

Employees

838

IOVA Metrics

BasicAdvanced
$847M
-
-$1.23
0.82
-

What the Analysts think about IOVA

Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.

Bulls say / Bears say

Iovance is expanding its iCTC manufacturing campus to support the production of TIL therapies for over 5,000 patients annually. The company is also developing a wider network able to serve more than 10,000 patients each year, placing it in a strong position to meet growing worldwide demand (GlobeNewswire).
Currently, the company holds about 280 granted or allowed U.S. and international patents covering Amtagvi and related TIL technologies, securing market exclusivity at least until 2042 and strengthening its position in the TIL cell therapy field (GlobeNewswire).
Iovance has submitted marketing authorization applications for lifileucel (Amtagvi) in the UK, EU, and Canada, with all applications accepted for review. Approvals expected in 2025 could enable access to more than 20,000 advanced melanoma patients outside the U.S. each year (GlobeNewswire).
Iovance’s first-quarter 2025 product revenue was $49.3 million, falling over 40% short of analyst expectations. As a result, the company cut its full-year 2025 revenue guidance from $450–475 million down to $250–300 million, signaling that Amtagvi’s commercial adoption has been weaker than expected (Investing.com).
The company plans to reduce its workforce by 19% in Q3 2025 to save more than $100 million annually, a cost-cutting move in response to sluggish sales, which will only extend its cash runway until Q4 2026 (BioPharma Dive).
Iovance reported a net loss of $116.2 million in Q1 2025 due to elevated operating expenses and limited capacity during scheduled maintenance, pointing to ongoing risk of high cash burn despite existing cash reserves (GuruFocus).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

IOVA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IOVA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IOVA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs